Sort   by:  
 Page size 
Smoking cessation is the most effective measure for reducing the risk of smoking-related diseases but switching to less harmful products (modified-risk tobacco products) can be an alternative for smokers who would otherwise not quit. In an 18-month chronic carcinogenicity/toxicity study in A/J mice ...
ORGANISM(S): Mus musculus (Mouse) 
2020-08-13 | PXD016460 | Pride
Smoking cessation is the most effective measure for reducing the risk of smoking-related diseases but switching to less harmful products (modified-risk tobacco products) can be an alternative for smokers who would otherwise not quit. In an 18-month chronic carcinogenicity/toxicity study in A/J mice ...
ORGANISM(S): Mus musculus (Mouse) 
2020-08-13 | PXD016466 | Pride
Single-cell RNA-seq data for Trex1 WT and KO mice from the tumor. Used for manuscript in submission at Science Advances.
ORGANISM(S): Mus musculus 
Single-cell RNA-seq data for Trex1 WT and KO mice from the heart. Used for manuscript in submission at Science Advances.
ORGANISM(S): Mus musculus 
Smoking cessation is the most effective measure for reducing the risk of smoking-related diseases but switching to less harmful products (modified-risk tobacco products) can be an alternative for smokers who would otherwise not quit. In an 18-month chronic carcinogenicity/toxicity study in A/J mice ...
ORGANISM(S): Mus musculus 
Smoking cessation is the most effective measure for reducing the risk of smoking-related diseases but switching to less harmful products (modified-risk tobacco products) can be an alternative for smokers who would otherwise not quit. In an 18-month chronic carcinogenicity/toxicity study in A/J mice ...
ORGANISM(S): Mus musculus 
Cigarette smoke (CS) causes adverse health effects that may occur shortly after smoking initiation and lead to the development of respiratory disease (chronic obstructive pulmonary disease), cardiovascular disease, and cancer. To reduce the risk of smokers developing smoking-related diseases, Philip...
ORGANISM(S): Mus musculus (Mouse) 
2019-06-18 | PXD010875 | Pride
Resistance to proteasome inhibitors (PIs) is a ubiquitous clinical concern in multiple myeloma. We proposed that signaling-level responses after PI would reveal new means to enhance efficacy. Unbiased phosphoproteomics after the PI carfilzomib surprisingly demonstrated the most prominent phosphory...
ORGANISM(S): Homo sapiens (Human) 
2020-02-21 | PXD012172 | Pride
Sort   by:  
 Page size